Title : Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Pub. Date : 2020 Aug 1

PMID : 31749144






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we aimed to assess the association between T2D, metformin use, and the risk of cancer in DM1 patients. Metformin immunoglobulin heavy diversity 1-7 Homo sapiens
2 DM1 patients with T2D, compared with those without T2D, were more likely to develop cancer (hazard ratio [HR]= 3.60, 95% confidence interval [CI]=1.18-10.97; p=0.02), but not if they were treated with metformin (HR=0.43, 95%CI=0.06-3.35; p=0.42). Metformin immunoglobulin heavy diversity 1-7 Homo sapiens
3 These results show an association between T2D and cancer risk in DM1 patients and may provide new insights into the possible benefits of Metformin use in DM1. Metformin immunoglobulin heavy diversity 1-7 Homo sapiens